Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event. METHODS: 171...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Walter, Robert Fred Henry, Sydow, Saskia Roxanne, Berg, Erika, Kollmeier, Jens, Christoph, Daniel Christian, Christoph, Sandra, Eberhardt, Wilfried Ernst Erich, Mairinger, Thomas, Wohlschlaeger, Jeremias, Schmid, Kurt Werner, Mairinger, Fabian Dominik
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6765394/
https://ncbi.nlm.nih.gov/pubmed/31576173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S194337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados